Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Sony Group Corp — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Sony Group Corp trades at $24.47 (market cap $140.46B). The key difference: Sony Group Corp is far larger — about 144.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Sony Group Corp pays a 0.65% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Sony Group Corp for 96 Days on average.
| MRVI | SONY | |
|---|---|---|
Market Cap | $972.90M | $140.46B |
Volume | 4,325,710 | 5,764,125 |
Sector | Health | Technology |
52-Week High | $9.00 | $30.26 |
52-Week Low | $2.83 | $19.32 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $1.08B | $138.37B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Sony trades at $24.36, up 0.41% with a bullish technical signal from moving averages. The company reported strong Q4 2025 and Q2 2026 earnings beats, though Q1 2026 missed expectations. Revenue remains stable around $12.96T with improving operating cash flow of $2.32T. Analyst sentiment is strongly positive with 11 buy ratings and no sell recommendations, while recent news highlights Sony's content moat and AI litigation developments.
Sony presents a compelling investment case with solid fundamentals and strong analyst support, though negative net income margin and ROE raise concerns. The stock's valuation appears reasonable with P/E of 20.65 and EV/EBITDA of 8.05. Key risks include content competition and AI-related legal challenges, while opportunities lie in Sony's entertainment ecosystem and strategic expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
